Artesunate
Locally Advanced Breast Cancer
Heidelberg UniversitySmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Locally Advanced Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bnt323 BioNTech SE | Phase 3 | BB |
bnt327 BioNTech SE | Phase 2 | B |
Rph-051 R-Pharm | Phase 3 | B |
Tenalisib Rhizen Pharmaceuticals SA | Phase 2 | B |
ZB-716 EnhancedBio USA Inc. | Phase 1/2 | CC |
rp12146 Rhizen Pharmaceuticals SA | Phase 1 | CC |
Same molecule, other indications
Artesunate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →